Lebrikizumab
Lebrikizumab is a monoclonal antibody medication that targets interleukin-13 (IL-13), a key cytokine involved in inflammatory skin conditions. It is primarily used to treat moderate-to-severe atopic dermatitis (eczema) in adults and adolescents. By blocking IL-13 signaling, it helps reduce inflammation, itching, and skin lesions associated with these conditions.
Lebrikizumab is an injectable biologic that treats atopic dermatitis by blocking IL-13, a protein that drives skin inflammation.
Key facts at a glance
- ATC
- D11AH10
- RxNorm
- 2693758
- Generic
- Lebrikizumab
- Class
- atc-d11
- Brands
- Ebglyss
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- prefilled syringe
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 250mg every 2 weeks
- Maximum
- consult physician
- Frequency
- every 2 weeks after initial dose
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 250mg every 2 weeks (for patients ≥40kg)
- Maximum
- consult physician
- Frequency
- every 2 weeks after initial dose
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 250mg every 2 weeks
- Maximum
- consult physician
- Frequency
- every 2 weeks after initial dose
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
8 groupspregnancy
first trimesteravoid if possible
use only if benefits outweigh risks to fetus
regular prenatal monitoring
Use with caution and monitor for adverse effects.
pregnancy
second trimestercontinue only if needed
continue only if already on therapy and benefits outweigh risks
routine prenatal care
Use with caution and monitor for adverse effects.
pregnancy
third trimesterconsider discontinuation
consider risks versus benefits; discuss with healthcare provider
fetal growth monitoring
Use with caution and monitor for adverse effects.
lactation
nursing mothersnot recommended
discontinue breastfeeding or discontinue therapy
monitor infant for adverse effects
pediatric_age
12 to 17 yearsno adjustment needed
approved for patients 12 years and older with atopic dermatitis
standard pediatric monitoring
geriatric
65 years and olderno adjustment needed
no dose adjustment required for geriatric patients
routine geriatric assessment
renal_impairment
mild to moderateno adjustment needed
no dose adjustment required as monoclonal antibodies are not renally cleared
standard monitoring
hepatic_impairment
mild to moderateno adjustment needed
no dose adjustment required for mild-moderate hepatic impairment
standard liver function monitoring
Statistics and clinical data
Drug class
Lebrikizumab is a monoclonal antibody that inhibits interleukin-13 (IL-13)
FDA approval year
FDA approved Lebrikizumab (Ebglyss) for atopic dermatitis
Common uses
Indicated for the treatment of moderate-to-severe atopic dermatitis
Mechanism of action
Binds to IL-13 cytokine, blocking its signaling
Lebrikizumab is approved for the treatment of moderate-to-severe atopic dermatitis (eczema) in adults and children aged 12 years and older who are candidates for systemic therapy. It may also be investigated for other conditions driven by IL-13, such as asthma or chronic obstructive pulmonary disease.
Lebrikizumab is an IgG4 monoclonal antibody that binds with high affinity to interleukin-13 (IL-13). It allows IL-13 to bind to its receptor IL-13Rα1 but blocks the formation of the signaling receptor complex with IL-4Rα, thereby inhibiting IL-13-mediated inflammatory responses that contribute to skin inflammation and barrier dysfunction in atopic dermatitis.
Lebrikizumab is administered as a subcutaneous injection, typically every 4 weeks after loading doses. Common side effects may include injection site reactions, conjunctivitis, and upper respiratory infections. As with other biologic therapies, there may be a risk of hypersensitivity reactions. Patients should be monitored for signs of infection during treatment. This medication should only be prescribed by qualified healthcare providers experienced in treating atopic dermatitis.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy